Epigenetic and Oncogenic Inhibitors target KRAS-mutant Colorectal Cancers
Elizabeth McKenna shared a post on X about a recent paper by Patrick Loi et al. titled “Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers” published in Cancer Discovery.
Authors: Patrick Loi, Amy Schade, Karen Cichowski et al.
“Now online in Cancer Discovery: Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-mutant Colorectal Cancers – by Patrick Loi, Amy Schade, Karen Cichowski and colleagues.”
Source: Elizabeth McKenna/X
More posts by Elizabeth McKenna in OncoDaily.
Elizabeth McKenna is the Executive Director of Cancer Discovery at the American Association for Cancer Research. Elizabeth earned her PhD from Harvard University and trained with Dr. Charles Roberts at the Dana-Farber Cancer Institute.
Her research was among the first to show that pediatric tumors characterized by mutations in chromatin remodelers are genomically stable and instead driven by epigenetic deregulation of key target genes.
She joined Cancer Discovery shortly after its launch as its founding Science Writer and became an editor in 2014, rising through the editorial ranks to become the journal’s Executive Editor in 2019. She is a member of the 40 Under 40 in Cancer Class of 2021.
